The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: To determine if lopinavir/ritonavir +/- hydroxychloroquine will reduce the proportion of participants who survive without requiring ventilatory support, 15 days after enrolment, in adult participants with non-critically ill SARS-CoV-2 infection. TRIAL DESIGN: ASCOT is an investigator-ini...

Descripción completa

Detalles Bibliográficos
Autores principales: Denholm, Justin T., Davis, Joshua, Paterson, David, Roberts, Jason, Morpeth, Susan, Snelling, Thomas, Zentner, Dominica, Rees, Megan, O’Sullivan, Matthew, Price, David, Bowen, Asha, Tong, Steven Y. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359440/
https://www.ncbi.nlm.nih.gov/pubmed/32665040
http://dx.doi.org/10.1186/s13063-020-04576-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359440/
https://www.ncbi.nlm.nih.gov/pubmed/32665040
http://dx.doi.org/10.1186/s13063-020-04576-9

Ejemplares similares